Tejnaksh Healthcare Limited
BSE: TEJNAKSH · Healthcare Service Provider · sector
Key numbers
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 31 companies in Healthcare Service Provider (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 33.9x in the last 12 months.
- Other income was 32% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹12.67 on 2026-10-26: -31.9% from the 52-week high, +19.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 3 | 3 | 3 | 3 |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 1 |
| OPM % | 22.1% | 22.7% | 25.8% | 26.3% | 27.8% | 26.0% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.21 | 0.12 | 0.15 | 0.14 | 0.17 | 0.13 |
| Revenue YoY | -20.6% | +0.4% | ||||
| Profit YoY | -29.4% | +8.0% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 8 | 7 | 8 | 13 | 11 | 11 |
| EBITDA | 4 | 3 | 4 | 4 | 3 | 3 |
| Net profit | 3 | 1 | 2 | 2 | 1 | 1 |
| EPS (₹) | 2.48 | 1.36 | 0.89 | 1.15 | 0.61 | 0.59 |
| Revenue growth | -9.6% | +12.0% | +56.9% | -16.4% | – | |
| Profit growth | -45.2% | +31.2% | +28.7% | -47.2% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +13.7% | – | – |
| Net profit | -3.8% | – | – |
| EPS | -23.5% | – | – |
| Share price | – | -30.5% (2y) | -35.7% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 26 | 27 |
| Borrowings | 1 | 0 |
| Cash & equivalents | 2 | 2 |
| Total assets | 30 | 30 |
| Fixed assets | 19 | 18 |
| Capital work in progress | – | 0 |
| Investments | 0 | 0 |
| Receivables | 2 | 2 |
| Inventory | 1 | 1 |
| Payables | 0 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 0 | 2 |
| Cash from investing | 4 | -0 |
| Cash from financing | -4 | -1 |
| Capex | 1 | 1 |
| Free cash flow | -0 | 1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 9.0% | 4.5% |
| ROCE % | 13.4% | 6.4% |
| Debtor days | 52 | 74 |
| Inventory days | 224 | 298 |
| Payable days | 85 | 86 |
| Cash conversion cycle (days) | 191 | 286 |
| Working capital days | 137 | 158 |
Peers in Healthcare Service Provider
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| LALPATHLAB | ₹31,100 cr | 57.2x | 12.4x | 23.1% | 29.6% | 27.9% | +11.1% | 0.71% |
| VIJAYA | ₹14,362 cr | 76.6x | 15.0x | 21.4% | 30.1% | 42.2% | +21.0% | 0.14% |
| METROPOLIS | ₹10,989 cr | 54.5x | 7.3x | 14.2% | 19.7% | 24.2% | +12.8% | 0.19% |
| THYROCARE | ₹7,491 cr | 42.6x | 12.8x | 31.1% | 39.7% | 31.4% | +16.3% | 1.99% |
| NEPHROPLUS | ₹6,095 cr | 71.6x | 5.5x | 6.9% | 13.4% | 22.7% | – | – |
| SURAKSHA | ₹1,628 cr | 45.4x | 6.7x | 15.7% | 25.2% | 31.4% | – | – |
| KRSNAA | ₹1,617 cr | 16.6x | 1.6x | 10.5% | 11.1% | 26.8% | +16.6% | 0.55% |
| 3BBLACKBIO | ₹1,193 cr | 21.2x | 3.7x | 18.7% | 22.8% | 34.9% | +127.8% | 0.29% |
| HEALTHX | ₹857 cr | – | 3.2x | -0.5% | – | – | – | – |
| TEJNAKSH | ₹26 cr | 21.5x | 0.9x | 4.7% | 6.8% | 26.5% | +13.7% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Healthcare Service Provider |
| Sub-industry | Healthcare Service Provider |
| Symbol | TEJNAKSH |
| BSE code | 539428 |
| ISIN | INE030T01027 |
| Face value | ₹5.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.